Cardioptimus
Innovative embolic deflection device enhances patient outcomes in cardiac procedures, mitigating stroke risks during transcatheter aortic valve replacement.
Innovative embolic deflection device enhances patient outcomes in cardiac procedures, mitigating stroke risks during transcatheter aortic valve replacement.
Cardioptimus is a biotechnology startup founded in 2012 that aims to revolutionize patient outcomes in cardiac procedures with its innovative embolic deflection device. The company's patent-pending technology deflects emboli towards the descending aorta, effectively reducing the risk of neurological issues such as stroke during transcatheter aortic valve replacement (TAVR) procedures and other cardiac surgeries. Their recent $150.00K Seed Round investment on 15 December 2014 from Missouri Technology Corporation (MTC) reflects investor confidence in the company's potential to make significant strides in the field of medical devices. Cardioptimus operates within the biotechnology, manufacturing, and medical devices industries, positioning itself as an innovative player in the healthcare space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $150.00K | 1 |
-logo.jpg){kind=logo}
|
15 Dec 2014 |
No recent news or press coverage available for Cardioptimus.
We care about your data, and we'd love to use cookies make your experience better.
